Accelovance Continues Oncology Leadership Growth with Addition of Former Global VP, Oncology from Wyeth/Pfizer and Bayer

Accelovance, Inc. (Accelovance), a contract research organization (CRO) focusing in oncology, vaccines, and general medicine, today announced that Mark S. Gelder, MD has joined the company as Vice President Medical Affairs, Oncology.

"I'm excited to announce Dr. Gelder's addition to our company, his expertise will be invaluable as we continue our growth within oncology," said Stephen Trevisan, Accelovance's President and CEO. "Mark joins Accelovance with an impressive depth and breadth of experience in oncology drug development which he will apply to advance the development goals of our oncology clients."

Dr. Gelder brings more than 25 years of oncology clinical trial and drug development experience to Accelovance, having provided significant contributions in the investigation, approval, and postmarketing development of multiple products. He has extensive regulatory experience with the FDA and EMA and has worked closely with community and academic oncologists and oncology cooperative groups. Dr. Gelder has also served in leadership roles in Development and Medical Affairs groups at both small and large pharmaceutical companies, including Inovio Pharmaceuticals, Heron Therapeutics, GE Healthcare, Bayer, Wyeth, and Pfizer.

Dr. Gelder is an alumnus of the University of Virginia School of Medicine and is a Fellow of the American College of Obstetrics and Gynecology. Following his Residency in Internal Medicine at the University of Virginia, he completed his Residency in Obstetrics and Gynecology and a Fellowship in Gynecologic Oncology at the University of Alabama, Birmingham (UAB). Following his training, he was an Attending Physician in Gynecologic Oncology at the University of Florida College of Medicine, where he was promoted to Division Director of Gynecologic Oncology. Dr. Gelder later joined a multispecialty oncology group in Charlotte, NC where he was the Director of Gynecologic Oncology at Presbyterian Cancer Center. During his years in practice, Dr. Gelder was active in clinical research with the Gynecologic Oncology Group (GOG). He is also a current member of numerous oncology societies including ASCO.

Dr. Gelder will be based in Accelovance's Philadelphia, PA office.

About Accelovance
Accelovance, Inc., headquartered in Rockville, MD, is an industry award-winning global Contract Research Organization (CRO) focused primarily in oncology, vaccines, and general medicine. As a clinical services provider to the pharmaceutical and biotechnology industries, Accelovance offers comprehensive clinical development services including management and implementation of Phase I-IV clinical trials and Clinical Engagement Solutions for recruitment, post-marketing surveillance, and long-term survival follow-up. For more information, visit the company's Web site at www.accelovance.com.

Press Contact: Michael Keens, VP Business Development 
240.238.4941
[email protected] 
Twitter: @Accelovance

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.